We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Guidance
Our Guidance explains the laws and regulations governing the development, manufacturing, marketing, and supply of therapeutic goods in Australia.
We recently introduced new features to improve your experience using Guidance on our website.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (32)
- Breast implant hub (1)
- Clinical trials (5)
- Committees and advisory bodies (2)
- Compliance and enforcement (30)
- Cosmetics (4)
- COVID-19 (11)
- Fees and payments (3)
- Import and export (9)
- Labelling and packaging (26)
- Legislation (9)
- Manufacturing (41)
- Medicinal cannabis hub (4)
- Metal-on-metal hip replacement implants hub (1)
- Safety monitoring and information (46)
- Scheduling (national classification system) (6)
- Shortages and supply disruptions (3)
- Sunscreens (2)
- Unique Device Identification (UDI) hub (2)
- Vaping hub (5)
- Weight loss products (1)
Search
292 result(s) found, displaying 101 to 125
-
GuidanceGuidance on requirements for Australian market authorisation of topical nasal decongestant medicines, for an OTC new medicine N2 application.
-
GuidanceGuidance on requirements for Australian market authorisation of preparations containing bromhexine hydrochloride, for an OTC new medicine N2 application.
-
GuidanceGuidance on the application process and information required for a substance to be evaluated for use in listed medicines.
-
GuidanceGuidance explaining how the Comparable Overseas Bodies report-based process is associated with shortened evaluation timeframes for applications.
-
GuidanceGuidance explaining how the method of preparation influences classification and whether autologous HCTs are eligible for exemptions.
-
GuidanceGuidance for biological sponsors on the eligibility criteria and supporting documents required for priority determination applications
-
GuidanceGuidance on submitting the CPD for prescription medicines.
-
GuidanceGuidance on how to interpret Essential Principle 13B and how it applies to your device.
-
GuidanceGuidance and examples to help you understand the regulatory framework for personalised medical devices.
-
GuidanceGuidance on requirements for Australian market authorisation of tablets containing aspirin, for an OTC new medicine N2 application.
-
GuidanceGuidance on complying with therapeutic goods advertising requirements.
-
GuidanceGuidance on requirements for Australian market authorisation of oral medicines containing ranitidine hydrochloride, for an OTC new medicine N2 application.
-
GuidanceGuidance on requirements for Australian market authorisation of topical imidazole antifungal medicines for dermal use, containing clotrimazole or miconazole nitrate, for an OTC New Medicine N2 application.
-
GuidanceGuidance for sponsors on the information required to establish quality for listed medicines.
-
GuidanceGuidance on requirements for Australian market authorisation of oral laxative medicines containing docusate sodium and/or sennosides, for an OTC new medicine N2 application.
-
GuidanceGuidance on requirements for Australian market authorisation of oral medicines containing loperamide hydrochloride, for an OTC New Medicine N2 application.
-
GuidanceGuidance on requirements for Australian market authorisation of oral medicines containing paracetamol, for an OTC New Medicine N2 application.
-
GuidanceGuidance on good manufacturing practice (GMP) compliance requirements for domestic and overseas manufacturers of medicines and biologicals.
-
GuidanceGuidance for sunscreen manufacturers who must comply with the PIC/S Guide to Good Manufacturing Practice for Medicinal Products (PE009-13).
-
GuidanceGuidance for sponsors or suppliers of biologicals in Australia on their ongoing responsibilities after a product is included on the Australian Register. of Therapeutic Goods (ARTG).
-
GuidanceGuidance about how to request reconsideration of 'reviewable' initial decisions by the Minister for Health.
-
GuidanceGuidance on requirements for Australian market authorisation of oral preparations containing dextromethorphan hydrobromide, for an OTC new medicine N2 application.
-
GuidanceGuidance for sponsors, manufacturers and providers of faecal microbiota transplant (FMT) products.
-
GuidanceGuidance explaining regulatory requirements for in-house in-vitro diagnostic medical devices (IVDs).
-
GuidanceGuidance applies to self-tests and point-of-care combo test kits.